Health

STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment

The story might be true, it might not be, but for now that’s less important to investors than Erasca’s $5 billion market value, which is a fraction of the $35 billion carried by Revolution Medicines.

✦ Extractive summary — built from the sources' own reporting•From 1 source•1 min read•Updated November 19, 2026, 11:30 AM UTC
Key points
  • On Friday, the company is presenting another slug of data on its drug, called ERAS-0015, at the EORTC-NCI-AACR “Triple” meeting in Barcelona.
  • To date, Erasca has backed up its claim with scant data from an early-stage study disseminated via press releases.
  • This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter.

Erasca’s pitch is straightforward: The U.S.-based biotech says it went to China and found a more potent, better-tolerated pan-RAS inhibitor than Revolution Medicines’ Rasonque.

The valuation disparity makes sense given Revolution’s lead, but it also stokes speculation that Erasca could be an attractive takeover target.

Additional details
  • Continue to STAT+ to read the full story….
  • Sign up here to get it delivered to your inbox.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 1 article from 1 outlet